Kenvue (KVUE) Stock
Fundamentals
Recent news

Kimberly-Clark offers remedies in bid for EU approval of Kenvue deal
Kimberly-Clark offers remedies in bid for EU approval of Kenvue deal
KVUE

5 Beaten-Down Dividend Kings Ready to Roar Back in 2027 (One Yields Over 5%)
5 Beaten-Down Dividend Kings Ready to Roar Back in 2027 (One Yields Over 5%)
KVUE

Better Dividend King to Buy and Hold: Johnson & Johnson or Kenvue?
Better Dividend King to Buy and Hold: Johnson & Johnson or Kenvue?
KVUE

Kimberly-Clark readies EU remedies in bid for Kenvue deal, sources say
Kimberly-Clark readies EU remedies in bid for Kenvue deal, sources say
KVUE
Technicals
Analyst Ratings
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $0.29 for this quarter. The company has not yet shared when it is announcing earnings.
% positive news of 10 articles
published over the past 14 days
Latest news

Kimberly-Clark offers remedies in bid for EU approval of Kenvue deal
Kimberly-Clark offers remedies in bid for EU approval of Kenvue deal
KVUE

5 Beaten-Down Dividend Kings Ready to Roar Back in 2027 (One Yields Over 5%)
5 Beaten-Down Dividend Kings Ready to Roar Back in 2027 (One Yields Over 5%)
KVUE

Better Dividend King to Buy and Hold: Johnson & Johnson or Kenvue?
Better Dividend King to Buy and Hold: Johnson & Johnson or Kenvue?
KVUE

Kimberly-Clark readies EU remedies in bid for Kenvue deal, sources say
Kimberly-Clark readies EU remedies in bid for Kenvue deal, sources say
KVUE

Kimberly-Clark's 54-Year Dividend Streak Faces Its Biggest Test Yet With $48.7 Billion Kenvue Deal
Kimberly-Clark's 54-Year Dividend Streak Faces Its Biggest Test Yet With $48.7 Billion Kenvue Deal
KVUE

Kenvue Declares Quarterly Cash Dividend
Kenvue Declares Quarterly Cash Dividend
KVUE

Tylenol use in pregnancy may be linked with uterus, ovary changes in daughters
Tylenol use in pregnancy may be linked with uterus, ovary changes in daughters
KVUE

Kenvue's Brand Strength and Innovation Strategy Support Growth
Kenvue's Brand Strength and Innovation Strategy Support Growth
KVUE

Should Investors Buy KVUE as Margin Gains Offset Slow Sales Growth?
Should Investors Buy KVUE as Margin Gains Offset Slow Sales Growth?
KVUE

Kenvue's Kimberly-Clark Deal Nears Closing With Key Risks Still Ahead
Kenvue's Kimberly-Clark Deal Nears Closing With Key Risks Still Ahead
KVUE
About Kenvue
Kenvue, Inc. is dedicated to providing impactful and personalized health solutions. Their product range caters to various needs, ranging from delicately cleansing a newborn's fingers during their initial bath to preserving skin vitality and offering relief from aches and pains. These products are designed to ensure safe and efficient care for everyday use, accommodating individuals at every life stage. The company places a strong emphasis on the integration of science at the heart of their caregiving approach, consistently uncovering genuine solutions for daily necessities and making them accessible to consumers.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Kirk L. Perry | CEO & Director | 1967 |
| Mr. Michael P. Wondrasch | Chief Technology & Data Officer | 1969 |
| Mr. Matthew Orlando | General Counsel | 1977 |
| Mr. Carlton Lawson | Group President of Europe, Middle East & Africa | 1969 |
| Ms. Heather R. Howlett | Interim CFO & Chief Accounting Officer | 1978 |
| Ms. Meredith Stevens | Chief Operations Officer | 1963 |
| Dr. Caroline Tillett Ph.D. | Chief Scientific Officer | 1972 |
| Ms. Sofya Tsinis | Head of Investor Relations | — |
| Mr. Jonathan Halvorson | Chief Digital & Marketing Officer | 1983 |
| Mr. Anil Agarwal | Head of Total Rewards | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
2 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 | -6.7 | +4.5 | -9.1 | -2.5 | -12.5 | -8.5 | +8.3 | +4.1 | ||||
| 2024 | -3.8 | -9.0 | +14.0 | -11.4 | +2.4 | -5.5 | +3.0 | +17.8 | +4.7 | +0.7 | +5.9 | -12.0 |
| 2025 | +0.0 | +11.2 | +0.8 | -1.2 | -0.4 | -11.6 | +2.2 | -4.1 | -21.9 | -9.3 | +7.5 | +0.2 |
| 2026 | +0.5 | +10.0 | -8.7 | +0.9 | -0.9 | +10.1 | -0.5 | -0.7 | -5.1 |



